Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.

dc.contributor.author

Zhu, Mei-Ling

dc.contributor.author

Wang, Mengyun

dc.contributor.author

Cao, Zhi-Gang

dc.contributor.author

He, Jing

dc.contributor.author

Shi, Ting-Yan

dc.contributor.author

Xia, Kai-Qin

dc.contributor.author

Qiu, Li-Xin

dc.contributor.author

Wei, Qing-Yi

dc.date.accessioned

2019-02-01T15:11:18Z

dc.date.available

2019-02-01T15:11:18Z

dc.date.issued

2012-01

dc.date.updated

2019-02-01T15:11:17Z

dc.description.abstract

BACKGROUND: Excision repair cross complementing group 5 (ERCC5 or XPG) plays an important role in regulating DNA excision repair, removal of bulky lesions caused by environmental chemicals or UV light. Mutations in this gene cause a rare autosomal recessive syndrome, and its functional single nucleotide polymorphisms (SNPs) may alter DNA repair capacity phenotype and cancer risk. However, a series of epidemiological studies on the association between the ERCC5 Asp1104His polymorphism (rs17655, G>C) and cancer susceptibility generated conflicting results. METHODOLOGY/PRINCIPAL FINDINGS: To derive a more precise estimation of the association between the ERCC5 Asp1104His polymorphism and overall cancer risk, we performed a meta-analysis of 44 published case-control studies, in which a total of 23,490 cases and 27,168 controls were included. To provide additional biological plausibility, we also assessed the genotype-gene expression correlation from the HapMap phase II release 23 data with 270 individuals from 4 ethnic populations. When all studies were pooled, we found no statistical evidence for a significantly increased cancer risk in the recessive genetic models (His/His vs. Asp/Asp: OR = 0.99, 95% CI: 0.92-1.06, P = 0.242 for heterogeneity or His/His vs. Asp/His + Asp/Asp: OR = 0.98, 95% CI: 0.93-1.03, P = 0.260 for heterogeneity), nor in further stratified analyses by cancer type, ethnicity, source of controls and sample size. In the genotype-phenotype correlation analysis from 270 individuals, we consistently found no significant correlation of the Asp1104His polymorphism with ERCC5 mRNA expression. CONCLUSIONS/SIGNIFICANCE: This meta-analysis suggests that it is unlikely that the ERCC5 Asp1104His polymorphism may contribute to individual susceptibility to cancer risk.

dc.identifier

PONE-D-12-03281

dc.identifier.issn

1932-6203

dc.identifier.issn

1932-6203

dc.identifier.uri

https://hdl.handle.net/10161/17982

dc.language

eng

dc.publisher

Public Library of Science (PLoS)

dc.relation.ispartof

PloS one

dc.relation.isversionof

10.1371/journal.pone.0036293

dc.subject

Humans

dc.subject

Neoplasms

dc.subject

Genetic Predisposition to Disease

dc.subject

Endonucleases

dc.subject

DNA-Binding Proteins

dc.subject

Nuclear Proteins

dc.subject

Transcription Factors

dc.subject

RNA, Messenger

dc.subject

Gene Expression Regulation, Neoplastic

dc.subject

Polymorphism, Single Nucleotide

dc.title

Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.

dc.type

Journal article

duke.contributor.orcid

Wei, Qing-Yi|0000-0002-3845-9445|0000-0003-4115-4439

pubs.begin-page

e36293

pubs.issue

7

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Population Health Sciences

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Medicine, Medical Oncology

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

pubs.publication-status

Published

pubs.volume

7

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.pdf
Size:
567.89 KB
Format:
Adobe Portable Document Format